These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9145737)

  • 1. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
    White MH; Anaissie EJ; Kusne S; Wingard JR; Hiemenz JW; Cantor A; Gurwith M; Du Mond C; Mamelok RD; Bowden RA
    Clin Infect Dis; 1997 Apr; 24(4):635-42. PubMed ID: 9145737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
    Noskin G; Pietrelli L; Gurwith M; Bowden R
    Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.
    Linden PK; Coley K; Fontes P; Fung JJ; Kusne S
    Clin Infect Dis; 2003 Jul; 37(1):17-25. PubMed ID: 12830404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.
    White MH; Bowden RA; Sandler ES; Graham ML; Noskin GA; Wingard JR; Goldman M; van Burik JA; McCabe A; Lin JS; Gurwith M; Miller CB
    Clin Infect Dis; 1998 Aug; 27(2):296-302. PubMed ID: 9709879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B colloidal dispersion.
    Patel R
    Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of amphotericin B colloidal dispersion. An overview.
    Herbrecht R; Letscher V; Andres E; Cavalier A
    Chemotherapy; 1999 Jun; 45 Suppl 1():67-76. PubMed ID: 10394023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
    Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
    Wingard JR; Kubilis P; Lee L; Yee G; White M; Walshe L; Bowden R; Anaissie E; Hiemenz J; Lister J
    Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
    Cordonnier C; Bresnik M; Ebrahimi R
    Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.
    Allende MC; Lee JW; Francis P; Garrett K; Dollenberg H; Berenguer J; Lyman CA; Pizzo PA; Walsh TJ
    Antimicrob Agents Chemother; 1994 Mar; 38(3):518-22. PubMed ID: 8203848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
    Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
    Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion.
    Herbrecht R; Letscher-Bru V; Bowden RA; Kusne S; Anaissie EJ; Graybill JR; Noskin GA; Oppenheim ; Andrès E; Pietrelli LA
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):460-6. PubMed ID: 11561801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Aspergillus spp.
    Gurwith M
    Chemotherapy; 1999 Jun; 45 Suppl 1():34-8. PubMed ID: 10394019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
    Timmers GJ; Zweegman S; Simoons-Smit AM; van Loenen AC; Touw D; Huijgens PC
    Bone Marrow Transplant; 2000 Apr; 25(8):879-84. PubMed ID: 10808210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis.
    Nihtinen A; Anttila VJ; Ruutu T; Juvonen E; Volin L
    Transpl Infect Dis; 2012 Feb; 14(1):24-32. PubMed ID: 21749589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.